Microbiota targeted therapy as alternative for prednisolone and biologicals in IBD patients during the current COVID-19 threat: a prospective study addressing the safety of Budesonide in combination with rifaximin or the Crohns Disease Exclusion Diet (CDED)

estlé0 个研究点目标入组 40 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

暂无简介。

•IBD patients - 18 years old - in patients where induction therapy is needed - chosen for one of the treatment options (antibiotic treatment or CDED), in consultation with the attending physician.

•Severe activity of IBD urging for rescue treatment to avoid surgery, active fistulas as main indication for current induction therapy of CD, pouchitis, signs of active infectious gastro-enteritis/enterocolitis or other signs of infectious agents in stool sample, abnormal renal function (eGFR <30 ml/min), pre-existent leucopenia (<2) or thrombopenia (<50), liver cirrhosis with a MELD score >20, any other condition which in the opinion of the treating physician would make the patient unsuitable for treatment according to this protocol/enrollment.

发起方

estlé